Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 386

1.

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM.

Biol Psychiatry. 2010 Nov 15;68(10):903-12. doi: 10.1016/j.biopsych.2010.08.025. Erratum in: Biol Psychiatry. 2011 Feb 15;69(4):389.

2.

Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM.

PLoS One. 2011 Jan 12;6(1):e16032. doi: 10.1371/journal.pone.0016032.

3.

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM.

JAMA Neurol. 2015 Sep;72(9):1029-42. doi: 10.1001/jamaneurol.2015.1285.

4.

Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.

Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, Blesa R, Clarimón J, Fortea J, Lleó A.

J Alzheimers Dis. 2014;42(1):157-67. doi: 10.3233/JAD-140240.

PMID:
24820015
5.

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.

Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, Blennow K, Kornhuber J, Maler JM, Zetterberg H, Spitzer P.

Alzheimers Res Ther. 2015 Dec 24;7:74. doi: 10.1186/s13195-015-0161-y.

6.

Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.

Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, Balasa M, Sánchez-Valle R, Molinuevo JL.

J Alzheimers Dis. 2014;42(3):901-8. doi: 10.3233/JAD-140624.

PMID:
25024322
7.

Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.

Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Bertelsen S, Huang KL, Sutphen CL, Tarawneh R, Fagan AM, Holtzman DM, Morris JC, Goate AM, Dougherty JD, Cruchaga C.

BMC Neurol. 2016 Nov 10;16(1):217.

8.

Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.

Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, Karydas A, Voltarelli L, Scherling C, Heuer H, Tartaglia MC, Miller Z, Coppola G, Ahlijanian M, Soares H, Kramer JH, Rabinovici GD, Rosen HJ, Miller BL, Meredith J, Boxer AL.

J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):244-50. doi: 10.1136/jnnp-2014-308004. Epub 2014 Jun 4.

9.

Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.

Melah KE, Lu SY, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Gleason CE, Dowling NM, Bratzke LC, Rowley HA, Sager MA, Asthana S, Johnson SC, Bendlin BB.

J Alzheimers Dis. 2016;50(3):873-86. doi: 10.3233/JAD-150897.

10.

Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.

Alcolea D, Martínez-Lage P, Sánchez-Juan P, Olazarán J, Antúnez C, Izagirre A, Ecay-Torres M, Estanga A, Clerigué M, Guisasola MC, Sánchez Ruiz D, Marín Muñoz J, Calero M, Blesa R, Clarimón J, Carmona-Iragui M, Morenas-Rodríguez E, Rodríguez-Rodríguez E, Vázquez Higuera JL, Fortea J, Lleó A.

Neurology. 2015 Aug 18;85(7):626-33. doi: 10.1212/WNL.0000000000001859. Epub 2015 Jul 15.

PMID:
26180139
11.

CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.

Alcolea D, Vilaplana E, Suárez-Calvet M, Illán-Gala I, Blesa R, Clarimón J, Lladó A, Sánchez-Valle R, Molinuevo JL, García-Ribas G, Compta Y, Martí MJ, Piñol-Ripoll G, Amer-Ferrer G, Noguera A, García-Martín A, Fortea J, Lleó A.

Neurology. 2017 Jul 11;89(2):178-188. doi: 10.1212/WNL.0000000000004088. Epub 2017 Jun 7.

PMID:
28592456
12.

Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease.

Alcolea D, Vilaplana E, Pegueroles J, Montal V, Sánchez-Juan P, González-Suárez A, Pozueta A, Rodríguez-Rodríguez E, Bartrés-Faz D, Vidal-Piñeiro D, González-Ortiz S, Medrano S, Carmona-Iragui M, Sánchez-Saudinós M, Sala I, Anton-Aguirre S, Sampedro F, Morenas-Rodríguez E, Clarimón J, Blesa R, Lleó A, Fortea J.

Neurobiol Aging. 2015 Jun;36(6):2018-23. doi: 10.1016/j.neurobiolaging.2015.03.001. Epub 2015 Mar 9.

PMID:
25865441
13.

Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.

Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM.

Ann Neurol. 2011 Aug;70(2):274-85. doi: 10.1002/ana.22448.

14.

Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.

Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM.

Alzheimers Res Ther. 2015 Sep 17;7(1):59. doi: 10.1186/s13195-015-0142-1.

15.

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.

Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, Nielsen HM.

PLoS One. 2015 Aug 13;10(8):e0135458. doi: 10.1371/journal.pone.0135458. eCollection 2015.

16.

CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.

Gispert JD, Monté GC, Falcon C, Tucholka A, Rojas S, Sánchez-Valle R, Antonell A, Lladó A, Rami L, Molinuevo JL.

Neurobiol Aging. 2016 Feb;38:47-55. doi: 10.1016/j.neurobiolaging.2015.10.022. Epub 2015 Nov 2.

PMID:
26827642
17.

Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.

Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM.

PLoS One. 2011 Apr 19;6(4):e18850. doi: 10.1371/journal.pone.0018850.

18.

Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases.

Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H.

Expert Rev Proteomics. 2017 Apr;14(4):285-299. doi: 10.1080/14789450.2017.1304217. Epub 2017 Mar 20. Review.

PMID:
28281838
19.

Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.

Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Goate AM; Alzheimer’s Disease Neuroimaging Initiative.

Biol Psychiatry. 2014 May 1;75(9):723-31. doi: 10.1016/j.biopsych.2013.11.032. Epub 2014 Jan 19.

20.

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.

Henjum K, Almdahl IS, Årskog V, Minthon L, Hansson O, Fladby T, Nilsson LN.

Alzheimers Res Ther. 2016 Apr 27;8(1):17. doi: 10.1186/s13195-016-0182-1.

Supplemental Content

Support Center